Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 15, 2014, 52 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $77.26 to $3,537,588.60.

Highlighted Stocks Traded by Insiders:

CSX (CSX) - FREE Research Report

Munoz Oscar, who is Executive Vice President & COO at CSX, sold 75,000 shares at $33.77 on Oct. 15, 2014. Following this transaction, the Executive Vice President & COO owned 513,467 shares meaning that the stake was reduced by 12.74% with the 75,000-share transaction.

Eliasson Fredrik J, who is EVP & Chief Financial Officer at CSX, sold 40,000 shares at $33.53 on Oct. 15, 2014. Following this transaction, the EVP & Chief Financial Officer owned 111,502 shares meaning that the stake was reduced by 26.4% with the 40,000-share transaction.

The shares most recently traded at $33.44, down $0.09, or 0.27% since the insider transaction. Historical insider transactions for CSX go as follows:

  • 4-Week # shares sold: 37,500
  • 12-Week # shares sold: 75,000
  • 24-Week # shares sold: 370,600

The average volume for CSX has been 6.4 million shares per day over the past 30 days. CSX has a market cap of $32.6 billion and is part of the services sector and transportation industry. Shares are up 13.35% year-to-date as of the close of trading on Wednesday.

CSX Corporation, together with its subsidiaries, provides rail-based transportation services in the United States and Canada. It offers traditional rail services, and transports intermodal containers and trailers. The stock currently has a dividend yield of 2.03%. The company has a P/E ratio of 17.6. Currently, there are 5 analysts who rate CSX a buy, no analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CSX - FREE

TheStreet Quant Ratings rates CSX as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full CSX Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan, who is SVP Software Development at Interactive Brokers Group, sold 1,800 shares at $23.80 on Oct. 15, 2014. Following this transaction, the SVP Software Development owned 703,217 shares meaning that the stake was reduced by 0.26% with the 1,800-share transaction.

The shares most recently traded at $24.06, up $0.26, or 1.1% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 14,400
  • 12-Week # shares sold: 49,500
  • 24-Week # shares sold: 76,500

The average volume for Interactive Brokers Group has been 396,000 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.3 billion and is part of the financial sector and financial services industry. Shares are down 3.08% year-to-date as of the close of trading on Wednesday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.7%. The company has a P/E ratio of 24.1. Currently, there are 2 analysts who rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Arrowhead Research (ARWR) - FREE Research Report

Anzalone Christopher Richard, who is President and CEO at Arrowhead Research, bought 16,000 shares at $6.32 on Oct. 15, 2014. Following this transaction, the President and CEO owned 260,173 shares meaning that the stake was boosted by 6.55% with the 16,000-share transaction.

The shares most recently traded at $6.82, up $0.50, or 7.33% since the insider transaction.

The average volume for Arrowhead Research has been 4.7 million shares per day over the past 30 days. Arrowhead Research has a market cap of $311.1 million and is part of the health care sector and drugs industry. Shares are down 40.37% year-to-date as of the close of trading on Wednesday.

Arrowhead Research Corporation, a biopharmaceutical company, develops targeted RNAi therapeutics in the United States. Currently, there are 4 analysts who rate Arrowhead Research a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARWR - FREE

TheStreet Quant Ratings rates Arrowhead Research as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Arrowhead Research Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null